Drug development

  • Osteoporosis drugs could reduce dementia risk, study suggests

    Osteoporosis drugs may lower dementia risk, with a study suggesting one widely used treatment could help prevent Alzheimer’s and related dementias. The research found that nitrogen-containing bisphosphonates, drugs widely used to treat osteoporosis, may significantly reduce the risk of Alzheimer’s disease and related dementias in older adults with osteoporosis or fragility fractures. Osteoporosis and dementia [...]

  • NewLimit raises US$45m for epigenetic longevity drugs

    NewLimit has secured an extra US$45m on a US$1.62bn valuation to advance epigenetic reprogramming medicines and prepare for a first clinical study in the coming years. The company is developing therapies to restore youthful function in older cells. Epigenetic reprogramming aims to reset chemical “tags” on DNA and its packaging proteins, restoring healthier gene activity [...]

  • Cell death discovery could lead to next-gen drugs for neurodegenerative conditions

    Researchers have discovered how to block cells dying, in a finding that could lead to new treatments for neurodegenerative conditions like Parkinson’s and Alzheimer’s. The team have identified a small molecule that can selectively block cell death. The findings lay the groundwork for next-generation neuroprotective drugs for degenerative conditions, which currently have no cure or [...]

  • AI helps unravel a cause of Alzheimer’s disease and identify a therapeutic candidate

    A new study found that a gene recently recognised as a biomarker for Alzheimer’s disease is actually a cause of it, due to its previously unknown secondary function - and have used artificial intelligence to help unravel this mystery of Alzheimer’s disease and discover a potential treatment that obstructs the gene’s moonlighting role. About one [...]